Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

New ER-modulatory isoflavonoids for cancer and other conditions

Nov. 6, 2002

Progenics receives funding for development of prostate cancer immunotherapies

Nov. 6, 2002

Epimmune licenses Valentis technology for use in DNA cancer vaccine products

Nov. 6, 2002

SuperGen to begin Orathecin NDA submission by year-end 2002

Nov. 5, 2002

Servier and ConjuChem report novel albumin-binding metalloproteinase inhibitors

Nov. 5, 2002

Progen receives clearance to begin PI-166 clinical trial

Nov. 5, 2002

Pharmacia researchers describe new CDK inhibitors for cancer and other indications

Nov. 5, 2002

Influence of renal dysfunction on safety profile of pemetrexed

Nov. 5, 2002

Pharmacokinetics of epothilone B assessed in patients with advanced cancer

Nov. 5, 2002

Clinical data on the proteasome inhibitor PS-341 in multiple myeloma updated

Nov. 5, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...